AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of earning call to be held on May 27, 2024 at 8.30 AM on Audited Financial Results for the 4th Quarter and year ended on March 31, 2024. AUROBINDO PHARMA LTD. - 524804 - Board Meeting Intimation for Consideration Of Audited Financial Results For The 4Th Quarter And Year Ended On March 31, 2024
AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 ,inter alia, to consider and approve Consideration and approval of, inter alia, audited financial results for the 4th quarter and the financial year ended on March 31, 2024. AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Submission of Annual Secretarial Compliance Report for the financial year ended 31 March 2024 AUROBINDO PHARMA LTD. - 524804 - Completion Of US FDA Inspection At Unit VII Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
Intimation of completion of US FDA Inspection at Unit VII of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, with one observation. AUROBINDO PHARMA LTD. - 524804 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Submission of Scrutinizer''s Report on the Postal Ballot voting results for appointment of Mr. M. R. Kumar as an Independent Director of the Company. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Submission of Order of NCLT approving the Scheme of Amalgamation of Mviyes Pharma Ventures Private Limited and Auronext Pharma Private Limited, wholly owned subsidiaries of the Company, with the Company. AUROBINDO PHARMA LTD. - 524804 - Completion Of US FDA Inspection At Unit II Of Eugia Pharma Specialities Ltd., A Wholly Owned Subsidiary
Intimation of completion of US FDA inspection at Unit II of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company. AUROBINDO PHARMA LTD. - 524804 - Intimation Under Regulation 30 Of SEBI Listing Regulations. Ref: 1. Our Letter Dated May 2, 2024 Informing About The Receipt Of Orders From Statutory / Regulatory Authorities Reversing ITC And Imposing Interest And Penalty. 2. Your Email Dated May 3, 2024 Seeking All The Details Under SEBI Circular
Submission of all the required details as per SEBI Circular dated July, 13, 2023 with regard to our disclosure submitted on May 2, 2024 informing about the receipt of order from statutory / regulatory authorities, the disclosure of which was submitted on May 2, 2024. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation of purchase of shares in Purple Bellflower Pty Limited, south Africa, a joint venture company and to make it a wholly owned subsidiary